|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Children's Oncology Group National Cancer Institute (NCI) |
|---|---|
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00028509 |
Purpose
RATIONALE: Assessing the effects of methotrexate on brain function in children may improve the ability to plan treatment and decrease side effects.
PURPOSE: Clinical trial to compare brain function of children who have been previously treated with methotrexate.
| Condition | Intervention |
|---|---|
|
Long-Term Effects Secondary to Cancer Therapy in Children Neurotoxicity |
Procedure: management of therapy complications |
| Study Type: | Observational |
| Official Title: | Assessment of Clinical and Neuroradiologic Evidence of Methotrexate Leukoencephalopathy in Children Treated on POG 9605 and 9201 |
| Estimated Enrollment: | 162 |
| Study Start Date: | July 2002 |
OBJECTIVES:
OUTLINE: This is a multicenter study.
More than 3 years after completion of therapy, patients undergo 9 different tests to assess intelligence, memory, learning, attention, concentration, processing of information, functioning, and visual-motor integration. Patients also undergo MRI of the head.
PROJECTED ACCRUAL: A total of 30-54 patients previously treated on protocol POG-9201 will be accrued for this study. A total of 60-108 patients previously treated on protocol POG-9605 will be accrued for this study.
Eligibility| Ages Eligible for Study: | 1 Year to 9 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Previously enrolled on POG-9201 or POG-9605
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy
Chemotherapy
Endocrine therapy
Radiotherapy
Surgery
Other
Contacts and Locations
Show 26 Study Locations| Study Chair: | Patricia K. Duffner, MD | Women and Children's Hospital of Buffalo |
More Information
| Study ID Numbers: | CDR0000069100, COG-ACCL0131, NCI-P01-0198 |
| Study First Received: | January 4, 2002 |
| Last Updated: | May 9, 2009 |
| ClinicalTrials.gov Identifier: | NCT00028509 History of Changes |
| Health Authority: | United States: Federal Government |
|
neurotoxicity long-term effects secondary to cancer therapy in children |
|
Neurotoxicity Syndromes Poisoning Neoplasm Metastasis Methotrexate Disorders of Environmental Origin |
|
Neoplasms Neoplastic Processes Pathologic Processes Neurotoxicity Syndromes |
Nervous System Diseases Poisoning Neoplasm Metastasis Disorders of Environmental Origin |